First demonstration set for 2011 Congress of Neurological Surgeons in Washington, D.C.
WINNIPEG, MB and RICHMOND, BC, Sept. 19, 2011 /CNW/ - IMRIS Inc.
(NASDAQ: IMRS) (TSX: IM) and MacDonald, Dettwiler and Associates Ltd.
(TSX: MDA) today announced an agreement for the final phases of
collaborative development of IMRIS's MR guided surgical robot, building
on the development work the two companies have completed to date.
IMRIS and MDA began work on a robotic surgery system in 2010 with the
goal of commercialization. The system is being designed initially to
perform microsurgery and biopsy-stereotaxy applications on the brain
with sub-millimeter precision by bringing the capabilities of surgical
robotics together with real time MR imaging in a fully integrated IMRIS
surgical suite under the full control of the neurosurgeon. Ultimately,
the technology is expected to extend into a broad range of surgical
The system features two robotic arms that can manipulate MR-compatible
tools at a microscopic level from a remote workstation. The surgeon
sees detailed three-dimensional images of the brain and the surgical
tools, and uses hand controllers equipped with enhanced touch sensation
that allow the surgeon to feel tissue through the robotic arms and
surgical tools and apply appropriate pressure as they operate.
A clinical trial utilizing the first generation of the robot on a cohort
of 120 patients is currently underway, led by Garnette Sutherland, MD,
Professor of Neurosurgery, at Calgary's Foothills Hospital. The first
public demonstration of IMRIS' robotic technology will be at the
Congress of Neurological Surgeons in Washington DC, where Dr.
Sutherland will share his experiences on October 3 and 4, 2011 with
delegates visiting the IMRIS booth.
Under the terms of the multimillion dollar agreement, MDA is IMRIS's
development and preferred manufacturing partner for image-guided
surgical robotics. The two companies have made significant progress in
advancing the new IMRIS image guided surgical robotic system toward
commercialization. Given current development plans, IMRIS anticipates
being in a position to seek regulatory approval as early as the second
quarter of 2012.
"Recognition of the benefits of medical robotics continues to grow, and
market demand for these value adding capabilities is increasing around
the world," said David Graves, CEO of IMRIS. "We believe the
availability of surgical robotics within IMRIS's image guided surgery
suites will prove very compelling for clinicians."
IMRIS (NASDAQ: IMRS) (TSX: IM) is a global leader in providing image
guided therapy solutions. These solutions feature fully integrated
surgical and interventional suites that incorporate magnetic resonance,
fluoroscopy and computed tomography to deliver on demand imaging during
procedures. The Company's systems serve the neurosurgical,
cardiovascular and neurovascular markets and have been selected by
leading medical institutions around the world.
This press release may contain or refer to forward-looking information
based on current expectations. In some cases, forward-looking
statements can be identified by terminology such as "anticipate",
"may", "expect", "believe", "prospective", "continue" or the negative
of these terms or other similar expressions concerning matters that are
not historical facts. These statements should not be understood as
guarantees of future performance or results. Such statements involve
known and unknown risks, uncertainties and other factors that may cause
actual results, performance or achievements to be materially different
from those implied by such statements. Although such statements are
based on management's reasonable assumptions, there can be no assurance
that actual results will be consistent with such statements.
Forward-looking statements are subject to significant risks and
uncertainties, and other factors that could cause actual results to
differ materially from expected results. These forward-looking
statements are made as of the date hereof and we assume no
responsibility to update or revise them to reflect new events or
MDA provides advanced information solutions that capture and process
vast amounts of data, produce essential information, and improve the
decision making and operational performance of business and government
organizations worldwide. Focused on markets and customers with strong
repeat business potential, MDA delivers a broad spectrum of information
solutions, ranging from complex operational systems, to tailored
information services, to electronic information products. The
Company's common shares trade on the Toronto Stock Exchange under the
symbol TSX: MDA.
This release contains forward-looking statements and information, which
reflect the current view of MacDonald, Dettwiler and Associates Ltd.
("MDA") with respect to future events and financial performance. The
forward-looking statements in this regard include statements regarding
the award of a contract. Any such forward-looking statements are based
on MDA's current expectations, estimates, projections and assumptions
in light of its experience and its perception of historical trends.
The factors and assumptions underlying the forward-looking statements
in this release include contracts not being terminated. Any such
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results to differ materially from
current expectations. MDA cautions readers that should certain risks or
uncertainties materialize, or should underlying assumptions prove
incorrect, actual results may vary significantly from those expected.
The risks that could cause actual results to differ from current
expectations include failure of third parties and subcontractors;
failure of systems to meet performance requirements and failure to
anticipate changes in technology, technical standards and offerings or
comply with the requisite standards.
For additional information with respect to certain of these risks or
factors, plus additional risks or factors, reference should be made to
MDA's continuous disclosure materials filed from time to time with
Canadian securities regulatory authorities, which are available online
at www.sedar.com or on MDA's website at www.mdacorporation.com. The Toronto Stock Exchange has neither approved nor disapproved the
form or content of this release.
SOURCE MacDonald, Dettwiler and Associates Ltd.
For further information: